We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Close

Biotechnology patent progress

Patent World Magazine

Biotechnology patent progress

Kathryn Robinson of Hempsons considers the most recent UK and EPO developments in stem cell and gene patenting

Article 6.1 of the Biotechnology Directive states, “Inventions shall be considered unpatentable where their commercial exploitation would be contrary to ordre public [meaning public policy] or morality; however, exploitation shall not be deemed to be so contrary merely because it is prohibited by law or regulation.” Article 6.2 of the Biotechnology Directive goes on to list, in a non-exhaustive way, what is considered unpatentable on these grounds:

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, please enter your details below to log in.

Enter your email address to log in as a user on your corporate account.
Remember me on this computer

Not yet an i-law subscriber?

Devices

Request a trial Find out more